Start-up of US-based study for treatment of Rotator Cuff Tears with Artelon® Tissue Reinforcement

Start-up of US-based study for treatment of Rotator Cuff Tears with Artelon®
Tissue Reinforcement

Västra Frölunda, Sweden, October 27, 2008

Artimplant has agreed with Tulsa Bone & Joint Associates, Tulsa, Oklahoma to
execute a clinical study on patients with soft tissue injuries in the rotator
cuff. 

The study comprises 25 patients with one year follow up and is estimated to be
completed the first quarter of 2010. Dr. Thomas Marberry has operated on their
first patient with Artelon® Tissue Reinforcement.

Dr. Thomas Marberry says;
”Tears of the rotator cuff tendons are one of the most common causes of shoulder
pain and disability in the upper extremity. In our study we will treat patients
with large or massive rotator cuff tears. I am excited with the benefit that
Artelon® Tissue Reinforcement may provide to my patients. The objective with our
study is to scientifically confirm the positive clinical experience we have with
the product so far.”

Hans Rosen, CEO Artimplant says;
“We are very enthusiastic about the cooperation with Dr. Marberry and his
colleagues at Tulsa Bone & Joint Associates. This study is an important step
forward in strengthening the scientific and commercial basis for the use of
Artelon® in rotator cuff tears.”


For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on October 27, 2008 at 08:45 AM (GMT+1).